Literature DB >> 23381627

Inhibition of p38/Mk2 signaling pathway improves the anti-inflammatory effect of WIN55 on mouse experimental colitis.

Yu Y Li1, Birol Yuece, Hua M Cao, Hong X Lin, Shuai Lv, Jie C Chen, Stephanie Ochs, Andrej Sibaev, Elisabeth Deindl, Claus Schaefer, Martin Storr.   

Abstract

P38/Mk2 (mitogen-activated protein kinase (MAPK)-activated protein kinase-2, also known as MAKAP kinase-2) is a member of the mitogen-activated protein kinases (MAPKs) family, and participates in inflammatory responses directly or indirectly. WIN55, 212-2 (WIN55) is a synthetic non-selective agonist of cannabinoid (CB) receptors with remarkable anti-inflammatory properties. This study was to explore the roles of WIN55 and p38/Mk2 signaling pathway in dextran sodium sulfate (DSS)-induced mouse colitis and ascertain their anti-inflammatory mechanisms. Colitis was induced in C57BL Mk2 gene homozygous deletion (Mk2-/-) and wild-type mice by replacing the drinking water with 4% DSS solution for 7 days. DSS-treated mice developed bloody stool, weight loss, and eye-visible multiple bleeding ulcers on colon mucosa. The mRNA expressions levels of TNF-α and IL-6, as well as the protein levels of p38 and its phosphorylated form (p-p38), were upregulated in the colon. The plasma levels of TNF-α, IL-6, cytokine-induced neutrophil chemoattractant-1 (CINC-1), monocyte chemoattractant protein-1 (MCP-1), and lung myeloperoxidase (MPO) activities were raised; however, all these changes were less severe in Mk2-/- mice. After WIN55 intervention, the Mk2-/- mice recovered faster and better from the induced colitis than their wild-type counterparts. The results indicate that the Mk2 homozygous deletion in mice impedes the induction of experimental colitis by DSS, confirming the notion that p38/Mk2 is involved in this inflammatory response. WIN55 protects mice against DSS-induced colitis, in particular when the p38/Mk2 pathway is obstructed, implying that the activation of CB system, together with blocking of p38/Mk2 pathway, serves as a potential drug target for colitis treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23381627     DOI: 10.1038/labinvest.2012.177

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  15 in total

1.  Mesenchymal MAPKAPK2/HSP27 drives intestinal carcinogenesis.

Authors:  Ana Henriques; Vasiliki Koliaraki; George Kollias
Journal:  Proc Natl Acad Sci U S A       Date:  2018-05-29       Impact factor: 11.205

Review 2.  Manipulation of the Endocannabinoid System in Colitis: A Comprehensive Review.

Authors:  Kristina L Leinwand; Mark E Gerich; Edward J Hoffenberg; Colm B Collins
Journal:  Inflamm Bowel Dis       Date:  2017-02       Impact factor: 5.325

3.  The Anti-Inflammatory Effect and Intestinal Barrier Protection of HU210 Differentially Depend on TLR4 Signaling in Dextran Sulfate Sodium-Induced Murine Colitis.

Authors:  Sisi Lin; Yongyu Li; Li Shen; Ruiqin Zhang; Lizhi Yang; Min Li; Kun Li; Jakub Fichna
Journal:  Dig Dis Sci       Date:  2016-12-19       Impact factor: 3.199

4.  Mitogen-activated protein kinase-activated protein kinase-2 (MK2) and its role in cell survival, inflammatory signaling, and migration in promoting cancer.

Authors:  Deri Morgan; Kiersten L Berggren; Colby D Spiess; Hannah M Smith; Ajay Tejwani; Scott J Weir; Christopher E Lominska; Sufi M Thomas; Gregory N Gan
Journal:  Mol Carcinog       Date:  2021-09-24       Impact factor: 4.784

5.  The endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cells.

Authors:  Kevin Wilhelmsen; Samira Khakpour; Alphonso Tran; Kayla Sheehan; Mark Schumacher; Fengyun Xu; Judith Hellman
Journal:  J Biol Chem       Date:  2014-03-18       Impact factor: 5.157

6.  A novel function for the MAP kinase SMA-5 in intestinal tube stability.

Authors:  Florian Geisler; Harald Gerhardus; Katrin Carberry; Wayne Davis; Erik Jorgensen; Christine Richardson; Olaf Bossinger; Rudolf E Leube
Journal:  Mol Biol Cell       Date:  2016-10-12       Impact factor: 4.138

7.  Alterations in biomechanical properties and microstructure of colon wall in early-stage experimental colitis.

Authors:  Xiaohui Gong; Xiaojuan Xu; Sisi Lin; Yu Cheng; Jianhua Tong; Yongyu Li
Journal:  Exp Ther Med       Date:  2017-06-14       Impact factor: 2.447

8.  Cannabinoid Receptor-2 Ameliorates Inflammation in Murine Model of Crohn's Disease.

Authors:  Kristina L Leinwand; Ashleigh A Jones; Rick H Huang; Paul Jedlicka; Daniel J Kao; Edwin F de Zoeten; Soumita Ghosh; Ruin Moaddel; Jan Wehkamp; Maureen J Ostaff; Jutta Bader; Carol M Aherne; Colm B Collins
Journal:  J Crohns Colitis       Date:  2017-10-27       Impact factor: 9.071

9.  MK2: an unrecognized regulator of tumor promoting macrophages in colorectal cancer?

Authors:  Eliseo F Castillo; Anita L Ray; Ellen J Beswick
Journal:  Macrophage (Houst)       Date:  2016-02-01

Review 10.  Role of Cannabinoids in Gastrointestinal Mucosal Defense and Inflammation.

Authors:  Klára Gyires; Zoltán S Zádori
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.